Teresa Klinowska

I serve as a Global Product Leader in Late Stage Oncology Research and Development at AstraZeneca. In my role, I lead global development teams for oncology compounds from the start of Phase 3 clinical trials through to launch and beyond.

I am most passionate about science and people. I began my career in academia but have spent the past two decades focused on oncology research and development at AstraZeneca because I am driven to help people living with cancer. My work at AstraZeneca is a perfect combination of my passions – we have an extremely robust product pipeline underpinned by exceptional science, and we take a truly patient-centric approach.

Over the years, I have held bioscience, translational science, principle scientist, tumour strategy leadership and project leadership roles in both early and late stage development, across AstraZeneca’s oncology franchises, with recent particular focus in breast cancer. I was the early project leader of the team that discovered a targeted therapy in EGFR+ lung cancer.

I also have significant expertise in breast cancer having led the team which defined strategy for breast cancer therapy development across AstraZeneca and MedImmune. I am currently leading an estrogen receptor targeting project in Late Development Oncology and have co-authored more than 45 peer-reviewed publications including papers in NatureClinical Cancer ResearchCancer Discovery and J Cell Science.

Before joining AstraZeneca, I gained my PhD in cell biology and embryonic development at the University of Manchester and worked at a start-up biotech focused on wound healing.

 

I am passionate about making a difference by bringing new medicines and innovations to patients, working collaboratively with industry, academia and the patients themselves.

Teresa Klinowska Global Product Leader, Oncology R&D

Honor

2024: 8th International PacRim Breast and Prostate Cancer Meeting


Shortlisted

2023: Finalist for AstraZeneca’s R&D award for the design and delivery of SERENA-3, a pre-surgical window of opportunity study in post menopausal women with early breast cancer (NCT04588298)

Award

2022: AstraZeneca R&D award for the design and delivery of SERENA-2, a randomised study in patients with metastatic breast cancer (NCT04214288)



Teresa Klinowska

CURRENT ROLE

Global Product Leader, Oncology R&D

2014 – 2019

Led global, cross-functional, oncology project teams from preclinical to Phase 3 preparation; also served as the global lead of the AstraZeneca/Medimmune breast cancer tumour strategy team

2011 – 2014

Held increasing levels of responsibility as a Principal Scientist within AstraZeneca’s Oncology Innovation Medicines Unit including building a global, cross-functional breast disease area team to define and execute strategy for breast and female cancers. During these years, also served as pre-clinical lead for Phase 2 assets building the scientific hypotheses and devising the strategy for clinical trials in breast, gastric, colorectal, renal, among others.

2009 – 2011

Served as a Translational Science Strategist within AstraZeneca Oncology and as Early Project Leader of the team that discovered a targeted therapy in EGFR+ lung cancer

 Featured publications